- Home
- AG vs BEAM Comparison
AG vs BEAM Comparison
Compare AG & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AG
- BEAM
- Stock Information
- Founded
- AG 1979
- BEAM 2017
- Country
- AG Canada
- BEAM United States
- Employees
- AG N/A
- BEAM N/A
- Industry
- AG Precious Metals
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AG Basic Materials
- BEAM Health Care
- Exchange
- AG Nasdaq
- BEAM Nasdaq
- Market Cap
- AG 1.9B
- BEAM 1.9B
- IPO Year
- AG N/A
- BEAM 2020
- Fundamental
- Price
- AG $5.95
- BEAM $24.70
- Analyst Decision
- AG Buy
- BEAM Buy
- Analyst Count
- AG 2
- BEAM 10
- Target Price
- AG $7.50
- BEAM $47.67
- AVG Volume (30 Days)
- AG 9.2M
- BEAM 1.1M
- Earning Date
- AG 02-20-2025
- BEAM 02-25-2025
- Dividend Yield
- AG 0.30%
- BEAM N/A
- EPS Growth
- AG N/A
- BEAM N/A
- EPS
- AG N/A
- BEAM N/A
- Revenue
- AG $525,212,999.00
- BEAM $349,643,000.00
- Revenue This Year
- AG N/A
- BEAM N/A
- Revenue Next Year
- AG $28.06
- BEAM $10.82
- P/E Ratio
- AG N/A
- BEAM N/A
- Revenue Growth
- AG N/A
- BEAM 328.73
- 52 Week Low
- AG $4.17
- BEAM $20.84
- 52 Week High
- AG $8.44
- BEAM $49.50
- Technical
- Relative Strength Index (RSI)
- AG 50.51
- BEAM 41.30
- Support Level
- AG $5.35
- BEAM $24.96
- Resistance Level
- AG $5.81
- BEAM $29.52
- Average True Range (ATR)
- AG 0.22
- BEAM 1.64
- MACD
- AG 0.01
- BEAM -0.51
- Stochastic Oscillator
- AG 51.72
- BEAM 9.71
About AG First Majestic Silver Corp. (Canada)
First Majestic Silver Corp is engaged in the production, development, exploration, and acquisition of mineral properties with a focus on silver and gold production in North America. It owns three producing mines, in Mexico consisting of the San Dimas Silver/Gold Mine, the Santa Elena Silver/Gold Mine and the La Encantada Silver Mine.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.